Dyslipidemia therapeutic agent
AssigneeKowa Company, Ltd.
InventorsYuta Inokuchi, Toshiaki Takizawa
Life of this patent
Estimating the term…
Abstract
This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-LDL cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and or treating dyslipidemia and the like, the drug composition including the following: (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either; and nicotinic acid and nicotinic-acid amide, collectively referred to as niacin, an ester derivative thereof, a salt thereof, or a solvate of any of these.
Claims7
A pharmaceutical composition for preventing and/or treating dyslipidemia, comprising:
- (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of either;
- and
- niacin, an ester derivative thereof, a salt of either, or a solvate of any of these.
A medicine for lowering LDL cholesterol, obtained by combining;
- a pharmaceutical composition comprising (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy) propyl]aminomethyl]phenoxy] butyric acid, a salt thereof, or a solvate of either, and a pharmaceutically acceptable carrier;
- and
- a pharmaceutical composition comprising nicotinic acid, nicotinic acid amide, which are collectively referred to as niacin, an ester derivative thereof, a salt of either, or a solvate of any of these, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.